A Phase 1, Randomized, Double-blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers
Latest Information Update: 09 Jun 2025
At a glance
- Drugs SGB 9768 (Primary) ; Sodium chloride
- Indications Immunological disorders
- Focus Adverse reactions; First in man
- Sponsors SanegeneBio
Most Recent Events
- 09 Jun 2025 New source identified and integrated Australian New Zealand Clinical Trials Registry (ACTRN12624000054516).
- 06 Aug 2024 According to a SanegeneBio media release, SGB-9768 has been dosed in multiple cohorts of subjects, demonstrating a favorable safety and tolerability profile.